HR 870

PhRMA Act of 2005

Congress: 109 (2005–2007, Ended)
Chamber: House
Policy Area: Health
Introduced: Feb 16, 2005
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Mar 14, 2005)
Official Text: https://www.congress.gov/bill/109th-congress/house-bill/870

Sponsor

Name: Rep. Stark, Fortney Pete [D-CA-13]
Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (13 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Berry, Marion [D-AR-1]	D · AR		Feb 16, 2005
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Mar 2, 2005
Rep. Israel, Steve [D-NY-2]	D · NY		Mar 2, 2005
Rep. Kucinich, Dennis J. [D-OH-10]	D · OH		Mar 10, 2005
Rep. McGovern, James P. [D-MA-3]	D · MA		Mar 10, 2005
Rep. Woolsey, Lynn C. [D-CA-6]	D · CA		Mar 10, 2005
Rep. Kildee, Dale E. [D-MI-5]	D · MI		Apr 27, 2005
Rep. McDermott, Jim [D-WA-7]	D · WA		Apr 27, 2005
Rep. Owens, Major R. [D-NY-11]	D · NY		Apr 27, 2005
Rep. Jackson-Lee, Sheila [D-TX-18]	D · TX		May 12, 2005
Rep. Sanders, Bernard [I-VT-At Large]	I · VT		May 17, 2005
Rep. Hinchey, Maurice D. [D-NY-22]	D · NY		Jun 17, 2005
Rep. Solis, Hilda L. [D-CA-32]	D · CA		Dec 16, 2005

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 14, 2005

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 16, 2005)

Pharmaceutical Research and Manufacturers Accountability Act of 2005 or the PhRMA Act of 2005 - Sets forth penalties for violations of acts prohibited under the Federal Food, Drug, and Cosmetic Act by an individual employed as the chief executive officer or as a member of the senior executive management group of the manufacturer of a drug, where the violation involves knowing concealment of evidence of a serious adverse drug experience.

Requires the Secretary of Health and Human Services to require the chief executive officer of the manufacturer of a Food and Drug Administration (FDA)-approved drug to annually: (1) attest that the manufacturer has disclosed to the Secretary all evidence of any serious adverse drug experience related to the drug; and (2) describe the process by which the manufacturer ensures that such disclosure has occurred. Allows the Secretary to withdraw an approval for such a drug for failure to provide such an attestation. Prohibits a chief executive officer of a manufacturer of such a drug from failing to provide such an attestation.

Requires the Secretary to direct a manufacturer or sponsor of a drug to complete any required postmarketing study of that drug by a specified deadline. Allows the Secretary to extend such a deadline. Sets forth penalties for failing to meet such a deadline.

Actions Timeline

- **Mar 14, 2005:** Referred to the Subcommittee on Health.
- **Feb 16, 2005:** Introduced in House
- **Feb 16, 2005:** Introduced in House
- **Feb 16, 2005:** Sponsor introductory remarks on measure. (CR E252)
- **Feb 16, 2005:** Referred to the House Committee on Energy and Commerce.